An interventional study of septum-guided anatomical segmentectomy in Non-Small Cell Lung Cancer, sponsored by Shanghai Chest Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Shanghai Chest Hospital · Not applicable, Interventional, and Treatment
This is a single-center, prospective, single-arm, open-label clinical trial evaluating the efficacy and safety of septum-guided segmentectomy in patients with 2-3 cm clinical stage IA3 peripheral non-small cell lung cancer (NSCLC) with a consolidation-to-tumor ratio (CTR) greater than 0.5 and up to 1.0. All eligible participants will undergo planned septum-guided anatomical segmentectomy or combined segmentectomy after intraoperative frozen-section confirmation of node-negative (N0) lymph node status. The primary endpoint is 3-year recurrence-free survival (RFS).
Lobectomy has long been the standard surgical treatment for operable early-stage non-small cell lung cancer (NSCLC). Randomized studies such as Japan Clinical Oncology Group 0802/West Japan Oncology Group 4607L (JCOG0802/WJOG4607L) and Cancer and Leukemia Group B 140503 (CALGB 140503) have supported sublobar resection for selected early-stage peripheral NSCLC, but most evidence is concentrated in tumors measuring 2 cm or less. For patients with 2-3 cm, solid-predominant clinical stage IA3 peripheral NSCLC, prospective evidence on the oncologic safety and pulmonary function benefit of segmentectomy remains limited.
septum-guided segmentectomy uses the intersegmental vein and intersegmental septal membrane as anatomical landmarks to standardize the intersegmental plane and achieve reproducible anatomical resection while preserving lung function. This study uses a single-arm objective performance criterion design. The planned enrollment is 100 participants, allowing for approximately 15% unevaluable or lost-to-follow-up participants, with a target evaluable sample of 83.
Before proceeding with segmentectomy, intraoperative frozen-section biopsy of protocol-specified lymph node stations is required to confirm node-negative (N0) disease. A positive frozen-section result will lead to conversion to lobectomy plus systematic lymph node dissection as standard treatment, and the participant will be recorded as a screen failure for the primary efficacy analysis while contributing to safety follow-up as specified in the protocol.
Participants will be followed after surgery at 1, 6, 12, 18, 24, 30, and 36 months, and annually during years 4 and 5. The primary endpoint is 3-year recurrence-free survival (RFS). Secondary and safety outcomes include pulmonary function changes, perioperative outcomes, microscopically margin-negative (R0) resection, lymph node assessment, local recurrence, overall survival, disease-free survival, quality of life, and postoperative adjuvant therapy.
Exclusion Criteria:
Participants with 2-3 cm clinical stage IA3 peripheral non-small cell lung cancer and consolidation-to-tumor ratio (CTR) \>0.5 to \<=1.0 will undergo planned septum-guided anatomical segmentectomy or combined segmentectomy after intraoperative frozen-section confirmation of node-negative (N0) lymph node status.
Procedure: septum-guided anatomical segmentectomy
septum-guided anatomical segmentectomy or combined segmentectomy performed for eligible peripheral clinical stage IA3 non-small cell lung cancer. The intersegmental vein and intersegmental septal membrane are used as anatomical landmarks to define the intersegmental plane. Intraoperative lymph node frozen-section biopsy must confirm node-negative (N0) status before segmentectomy proceeds; positive nodal disease leads to lobectomy plus systematic lymph node dissection as standard treatment.
3-Year Recurrence-Free Survival
Recurrence-free survival is defined as the time from surgery to the first imaging- or pathology-confirmed recurrence, metastasis, or death from any cause. The primary analysis will estimate the 3-year recurrence-free survival rate using the Kaplan-Meier method.
Time frame: Up to 3 years after surgery
Change in Forced Expiratory Volume in 1 Second at 6 Months
Change in forced expiratory volume in 1 second (FEV1) from preoperative baseline to 6 months after surgery, reported as absolute and percent predicted values according to pulmonary function testing.
Time frame: Baseline and 6 months after surgery
Change in Forced Expiratory Volume in 1 Second at 12 Months
Change in forced expiratory volume in 1 second (FEV1) from preoperative baseline to 12 months after surgery, reported as absolute and percent predicted values according to pulmonary function testing.
Time frame: Baseline and 12 months after surgery
Change in Forced Vital Capacity at 6 Months
Change in forced vital capacity (FVC) from preoperative baseline to 6 months after surgery, reported as absolute and percent predicted values according to pulmonary function testing.
Time frame: Baseline and 6 months after surgery
Change in Forced Vital Capacity at 12 Months
Change in forced vital capacity (FVC) from preoperative baseline to 12 months after surgery, reported as absolute and percent predicted values according to pulmonary function testing.
Time frame: Baseline and 12 months after surgery
Change in Single-Breath Diffusing Capacity of the Lung for Carbon Monoxide at 6 Months
Change in single-breath diffusing capacity of the lung for carbon monoxide (DLCO SB) from preoperative baseline to 6 months after surgery.
Time frame: Baseline and 6 months after surgery
Change in Single-Breath Diffusing Capacity of the Lung for Carbon Monoxide at 12 Months
Change in single-breath diffusing capacity of the lung for carbon monoxide (DLCO SB) from preoperative baseline to 12 months after surgery.
Time frame: Baseline and 12 months after surgery
Operative Time
Operative time measured in minutes from surgical incision to closure, or according to the start and end times recorded in the operative or anesthesia record.
Time frame: Intraoperative
Intraoperative Blood Loss
Estimated intraoperative blood loss measured in milliliters according to the operative or anesthesia record.
Time frame: Intraoperative
Chest Tube Duration
Duration of postoperative chest tube placement measured in days from surgery to chest tube removal.
Time frame: From surgery until chest tube removal, assessed up to 30 days
Postoperative Length of Stay
Length of postoperative hospital stay measured in days from surgery to discharge.
Time frame: From surgery until hospital discharge, assessed up to 30 days
Postoperative Complications
Incidence and severity of postoperative complications within 30 days after surgery, graded according to the Clavien-Dindo classification.
Time frame: Up to 30 days after surgery
Microscopically Margin-Negative Resection Rate
Proportion of participants with microscopically margin-negative resection based on the final pathology report.
Time frame: Day of final pathology report, up to 30 days after surgery
Lymph Node Assessment Quality
Quality of lymph node assessment, including the number and stations of sampled or dissected lymph nodes as documented in the operative and pathology records.
Time frame: Day of final pathology report, up to 30 days after surgery
Surgical Margin Distance
Distance from the tumor to the surgical resection margin, assessed from operative and final pathology findings.
Time frame: Perioperative period and day of final pathology report, up to 30 days after surgery
Local Recurrence Rate
Proportion of participants with local recurrence, including recurrence at the surgical margin, ipsilateral thoracic cavity, or hilar or mediastinal lymph nodes.
Time frame: Up to 5 years after surgery
Overall Survival
Overall survival is defined as the time from surgery to death from any cause.
Time frame: Up to 5 years after surgery
Disease-Free Survival
Disease-free survival is defined as the time from surgery to recurrence, metastasis, or death from any cause.
Time frame: Up to 5 years after surgery
Global Health Status and Quality of Life Score Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
The global health status and quality of life scale of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 will be reported as one score. The score ranges from 0 to 100; higher scores indicate better global health status and quality of life.
Time frame: Baseline, 6 months, 12 months, 36 months, and 60 months after surgery
Postoperative Adjuvant Therapy
Proportion of participants receiving postoperative adjuvant therapy and the type of adjuvant regimen administered during follow-up.
Time frame: Up to 5 years after surgery
Lung Cancer Symptom Burden Summary Score Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13
Lung cancer symptom burden will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13. A prespecified summary score will be calculated as the mean of the available questionnaire symptom item or scale scores after linear transformation to a 0 to 100 scale; higher scores indicate worse lung cancer symptom burden.
Time frame: Baseline, 6 months, 12 months, 36 months, and 60 months after surgery
No study locations are listed for this record.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung→
Shanghai Chest Hospital